Cristina Cruz

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Thomas Powles, Joseph P. Eder, Gregg Fine et al. · Nature · 2014 · 2.4K citations

Medicine, Oncology, Pharmacology +12

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Leisha A. Emens, Cristina Cruz, Joseph P. Eder et al. · JAMA Oncology · 2018 · 793 citations · Full text

Medicine, Oncology, Pharmacology +17

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

Cristina Cruz, Marta Castroviejo‐Bermejo, Sara Gutiérrez‐Enríquez et al. · Annals of Oncology · 2018 · 427 citations · Full text

Medicine, Molecular Biology, Oncology +17

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Shawn F. Johnson, Cristina Cruz, Ann Katrin Greifenberg et al. · Cell Reports · 2016 · 286 citations · Full text

Medicine, Cancer Biology, Oncology +16

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara et al. · EMBO Molecular Medicine · 2018 · 274 citations · Full text

Medicine, Cancer Biology, Oncology +9